• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂肪萎缩在临床上变得明显需要减少多少脂肪?

How much fat loss is needed for lipoatrophy to become clinically evident?

作者信息

Podzamczer Daniel, Ferrer Elena, Martínez Esteban, Del Rio Luis, Rosales Joaquín, Curto Jordi, Ribera Esteban, Barrufet Pilar, Llibre Josep M, Aranda Miquel

机构信息

Infectious Disease Service, Hospital Universitari de Bellvitge, c/Feixa Llarga s/n. L'Hospitalet, Barcelona 08907, Spain.

出版信息

AIDS Res Hum Retroviruses. 2009 Jun;25(6):563-7. doi: 10.1089/aid.2008.0264.

DOI:10.1089/aid.2008.0264
PMID:19500014
Abstract

The objective of this study was to evaluate how much limb fat is needed to be lost for lipoatrophy to become clinically evident. Antiretroviral drug-naive patients from a randomized trial comparing stavudine or abacavir plus lamivudine and efavirenz, who had subjective assessment to detect clinically evident lipoatrophy (standardized questionnaire) and objective measurements of limb fat (dual X-ray absorptiometry) at baseline, 48 weeks, and 96 weeks were included. ROC curves were used to assess the sensitivity and specificity of several cut-off values of absolute and percent limb fat loss for diagnosing lipoatrophy. Of 54 patients included, 13 (24%) had subjective lipoatrophy at 96 weeks. After 96 weeks, median limb fat change was -2.3 kg (interquartile range: -5.2, +0.2) and 0.4 kg (interquartile range: -7.2, +3.4) in patients with and without lipoatrophy, respectively. Median percent limb fat change was -45.5% (interquartile range: -78.0, +3.7) and 5.5% (interquartile range: -62.8, +95.6), respectively. The cut-off values of absolute and percent limb fat loss showing the best sensitivity and specificity values were -1.5 kg (sensitivity, 77%; specificity, 76%) and -30% (sensitivity, 85%; specificity, 73%). At least 30% limb fat is needed to be lost in HIV-infected patients for lipoatrophy to become clinically evident.

摘要

本研究的目的是评估需要减少多少肢体脂肪才会使脂肪萎缩在临床上显现出来。纳入了一项随机试验中未接受过抗逆转录病毒药物治疗的患者,该试验比较了司他夫定或阿巴卡韦加拉米夫定与依非韦伦,这些患者在基线、48周和96周时进行了主观评估以检测临床上明显的脂肪萎缩(标准化问卷)和肢体脂肪的客观测量(双能X线吸收法)。采用ROC曲线评估诊断脂肪萎缩时绝对和百分比肢体脂肪减少的几个临界值的敏感性和特异性。在纳入的54例患者中,13例(24%)在96周时出现主观脂肪萎缩。96周后,有和没有脂肪萎缩的患者肢体脂肪变化中位数分别为-2.3 kg(四分位间距:-5.2,+0.2)和0.4 kg(四分位间距:-7.2,+3.4)。肢体脂肪变化百分比中位数分别为-45.5%(四分位间距:-78.0,+3.7)和5.5%(四分位间距:-62.8,+95.6)。显示出最佳敏感性和特异性值的绝对和百分比肢体脂肪减少的临界值分别为-1.5 kg(敏感性77%;特异性76%)和-30%(敏感性85%;特异性73%)。对于HIV感染患者,肢体脂肪至少需要减少30%才会使脂肪萎缩在临床上显现出来。

相似文献

1
How much fat loss is needed for lipoatrophy to become clinically evident?脂肪萎缩在临床上变得明显需要减少多少脂肪?
AIDS Res Hum Retroviruses. 2009 Jun;25(6):563-7. doi: 10.1089/aid.2008.0264.
2
Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy.对一组接受联合抗逆转录病毒治疗的HIV感染患者面部脂肪萎缩变化的客观评估。
HIV Clin Trials. 2008 Nov-Dec;9(6):399-406. doi: 10.1310/hct0906-399.
3
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.一项关于替诺福韦酯或阿巴卡韦替代核苷类似物用于脂肪萎缩患者的随机对照试验。
AIDS. 2006 Oct 24;20(16):2043-50. doi: 10.1097/01.aids.0000247574.33998.03.
4
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.从胸腺嘧啶核苷类似物转换为阿巴卡韦2年后HIV感染患者脂肪萎缩的可逆性:MITOX扩展研究
AIDS. 2004 Apr 30;18(7):1029-36. doi: 10.1097/00002030-200404300-00011.
5
Changes in facial fat in HIV-related lipoatrophy, wasting, and weight gain measured by magnetic resonance imaging.通过磁共振成像测量的与HIV相关的脂肪萎缩、消瘦和体重增加中面部脂肪的变化。
HIV Clin Trials. 2007 Jul-Aug;8(4):227-34. doi: 10.1310/hct0804-227.
6
Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.从齐多夫定/拉米夫定制剂转换为替诺福韦/恩曲他滨对脂肪萎缩的影响:RECOMB 研究。
HIV Med. 2013 Jul;14(6):327-36. doi: 10.1111/hiv.12011. Epub 2013 Jan 9.
7
Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection.HIV脂肪萎缩中的线粒体RNA和DNA改变与抗逆转录病毒疗法有关,而非与HIV感染有关。
Antivir Ther. 2008;13(5):715-22.
8
Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences.人类免疫缺陷病毒治疗引起的脂肪组织病理学和脂肪萎缩:流行情况和代谢后果。
Clin Infect Dis. 2010 Sep 1;51(5):591-9. doi: 10.1086/655765.
9
Objective amount of limb fat in HIV-infected subjects with subjective diagnosis of lipoatrophy.HIV 感染者肢体脂肪的客观数量与主观诊断的脂肪萎缩。
HIV Med. 2009 Apr;10(4):257-61. doi: 10.1111/j.1468-1293.2008.00680.x. Epub 2009 Jan 23.
10
Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy.脂肪因子水平的早期变化和肢体脂肪基线可能预测抗逆转录病毒治疗开始后2年内的HIV脂肪萎缩。
HIV Med. 2008 Feb;9(2):101-10. doi: 10.1111/j.1468-1293.2007.00527.x.

引用本文的文献

1
Adipose Tissue Dysfunction and Energy Balance Paradigms in People Living With HIV.脂肪组织功能障碍与 HIV 感染者的能量平衡范式。
Endocr Rev. 2024 Mar 4;45(2):190-209. doi: 10.1210/endrev/bnad028.
2
HIV and antiretroviral therapy-related fat alterations.HIV 和抗逆转录病毒治疗相关的脂肪改变。
Nat Rev Dis Primers. 2020 Jun 18;6(1):48. doi: 10.1038/s41572-020-0181-1.
3
Differential relationships of hepatic and epicardial fat to body composition in HIV.HIV患者肝脏脂肪和心外膜脂肪与身体成分的差异关系。
Physiol Rep. 2017 Oct;5(19). doi: 10.14814/phy2.13386. Epub 2017 Oct 16.
4
Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.拉替拉韦或蛋白酶抑制剂起始治疗后的身体成分变化:ACTG A5260s研究
Clin Infect Dis. 2016 Apr 1;62(7):853-62. doi: 10.1093/cid/ciw017. Epub 2016 Jan 20.
5
Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES.1998 - 2007年接受抗逆转录病毒治疗前的HIV感染者与普通人群之间的人体测量差异:艾滋病临床试验组纵向关联随机试验(ALLRT)队列和美国国家健康与营养检查调查(NHANES)
PLoS One. 2013 Jun 3;8(6):e65306. doi: 10.1371/journal.pone.0065306. Print 2013.
6
Lipodystrophy in HIV patients: its challenges and management approaches.HIV患者的脂肪代谢障碍:挑战与管理方法
HIV AIDS (Auckl). 2011;3:135-43. doi: 10.2147/HIV.S14562. Epub 2011 Dec 14.
7
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.接受阿巴卡韦-拉米夫定或替诺福韦-恩曲他滨联合阿扎那韦/利托那韦或依非韦伦治疗的受试者外周和中心脂肪变化:ACTG 研究 A5224s。
Clin Infect Dis. 2011 Jul 15;53(2):185-96. doi: 10.1093/cid/cir324.
8
LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.接受高效抗逆转录病毒治疗的 HIV 感染儿童中的脂肪营养不良综合征
South Afr J HIV Med. 2009 Dec;10(4):76-80. doi: 10.4102/sajhivmed.v10i4.264.